Melatonin, immune modulation and aging

Autoimmunity

Volumn 26, Issue 1, 1997, Pages 43-53

  Zhang, Zhen ^a   Inserra, Paula F ^a   Liang, Bailin ^a   Ardestani, Sussan K ^a   Elliott, Kerry K ^a   Molitor, Mark ^a   Watson, Ronald Ross ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

AIDS; Cancer; Immunity; Immunoregulation; Melatonin

Indexed keywords

HORMONE; INTERLEUKIN 2; LYMPHOCYTE RECEPTOR; MELATONIN;

AGING; ANTINEOPLASTIC ACTIVITY; CANCER; CELLULAR IMMUNITY; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION; NONHUMAN; PHOTOPERIODICITY; PINEAL BODY; REVIEW; SOLID TUMOR;

EID: 0030703233     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916939709009549     Document Type: Review

References (90)

1. Savino, W., Dardenne, M., Papienik, M., et al. (1982). Thymic hormone-containing cells. Characterization and localization of serum thymic factor in young mouse thymus by monoclonal antibodies. J Exp Med, 156, 628-32.
2. Champion, S., Imhof, B. A., Savagner, P., et al. (1986). The embryonic thymus produces chemotatic peptides involved in the homing of hemopoietic precursors. Cell, 44, 781-90.
3. Gupta, D. (1990). An integrated communication network between the immune and neuroendocrine system. In: Gupta D., Wollmanna H. H., Ranke M. B., editors. Neuroendocrinology: New Frontiers. New York: Brain Research Promotion, 265-85.
4. Pierpaoli, W. and Yi, C. X. (1990). The involvement of pineal gland and melatonin in immunity and aging. I. Thymus mediated, immunereconstituting and antiviral activity of thyrotropin releasing hormone. J Neuroimmunol, 27, 99-109.
5. Maestrone, G. J. M., Conti, A. and Pierpaoli, W. (1987). Role of the pineal gland in immunity. II. Melatonin enhances the antibody response via an poiatergic mechanism. Clin Exp Immunol, 68, 384-91.
6. Dardenne, M., Itoh, T. and Homo-Delarche, F. (1986). Presence of glucocorticoid receptors in cultured thymic epithelial cells. Cell Immunol, 100, 112-20.
7. Ban, E., Gangerault, M. C., Jammes, H., et al. (1991). Specific binding sites for growth hormone in cultured mouse thymic epithelial cells. Life Sci, 48, 2141-8.
8. Persengiev, S., Marinova, C. H. and Patchev, V. (1991a). Steroid hormone receptor in the thymus: A site of immunomodulatory action of melatonin. Int J Biochem, 23, 1483-5.
9. Persengiev, S., Patchev, V. and Velev, B. (1991b). Melatonin effects on thymus steroid receptors in the course of primary antibody response: Significance of circulating glucocorticoid levels. Int J Biochem, 23, 1487-9.
10. Harbour, D. V., Smith, E. M. and Meyer, W. J. (1988). Thyrotropin releasing hormone (TRH) receptors in the immune system. Soc Neurosci Abstr, 14, 3043.
11. Lesnikov, V. A. and Korneva, E. A. (1992). The involvement of pineal gland and melatonin in immunity and aging: II. Thyrotropin-releasing hormone and melatonin forestall involution and promote reconstitution of the thymus in anterior hypothalamic area (AHA)- lesioned mice. Int J Neurosci, 62, 141-53.
12. Breder, C. D., Dinarello, C. A. and Saper, C. B. (1988). Interleukin-1β immuno-reactive innervation of the human hypothalamus. Science, 240, 321-4.
13. Lechan, R. M., Toni, R., Clark, B. D., et al. (1990). Immunoreactive interleukin-1 localization in the rat forebrain. Brain Res, 514, 135-40.
14. Dardenne, M., Savino, W.,Gagnerault, M. C., et al. (1988). Effect of endogenous opioids on the thymic epithelial cells. Cell Immunol Bioch Suppl., 12D, 310-8.
15. Wybran, D., Appleboom, T., Famaey, J. P., et al. (1979). Suggestive evidence for morphine and methionine-enkephalin receptor-like structures on normal blood T lymphocytes. J Immunol, 123, 1068-70.
16. Grorges, J. M. (1991). Maestroni, Ario Conti. Anti-stress role of the melatonin-immuno-opioid network: evidence for a physiological mechanism involving T cell-derived, immuno-reactive β-endorphin and met-enkephalin binding to thymic opioid receptors. Int J Neurosci, 61, 289-98.
17. Ovadia, H., Nitsan, P. and Abramsky, O. (1989). Characterization of opiate binding sites on membranes of rat lymphocytes. J Neuroimmunol, 21, 93-102.
18. Maestroni, G. J. M. and Conti, A. (1990). The pineal neurohormone melatonin stimulates activated CD4+ Thy+ cells to release opioid agonists with immunoenhancing and anti-stress properties. J Neuroimmunol, 28, 167-76.
19. Carvo, J. R., Rafii-El-Idrissi, M., Pozo, D., et al. (1995). Immunomodulatory role of melatonin: specific binding sites in human and rodent lymphoid cells. J Pineal Res, 18, 119-26.
20. Lopez-Gonzalez, M. A., Calvo, J. R., Osuna, C., et al. (1992a). Interaction of melatonin with human lymphocytes: Evidence for binding sites coupled to potentiation of cyclic AMP stimulation by vasoactive intestinal peptide and activation of cyclic GMP production. J Pineal Res, 12, 97-104.
21. Calvo, J. R., Guerrero, J. M., Molinero, P., et al. (1986). Interaction of vasoactive intestinal peptide (VIP) with human peripheral blood lymphocytes: specific binding and cyclic AMP production. Gen Pharmacol, 17, 185-9.
22. Guerrero, J. M., Prieto, J. C, Eloza, F. L., et al (1981). Interaction of vasoactive intestinal peptide with human blood mononuclear cells. Mol Cell Endocrinol, 21, 151-60.
23. Ottaway, C. A. (1987). Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. Immunology. 62, 291-7.
24. Del Prete, G., Maggi, E. and Romagnani. S. (1994). Human ThI and Th2 cells: Functional properties, mechanisms of regulation and role in disease. Lab Invest, 70, 299-307.
25. Stanisz, A. M., Befus. D. and Bienenstock, J. (1986). Differential effects of vasoactive intestinal peptide, subtance P. and somatostatin on immunoglobulin synthesis and proliferation by lymphocytes from Peyer's patches, mesenteric lymph nodes and spleen. J Immunol, 136, 152-6.
26. Gomzalez-Haba, M. G., Garcia, M. S., Calvo, J. R., et al. (1995). High-affinity binding of melatonin by human circulating T lymphocytes (CD4+). FASEB J., 9, 1331-5.
27. Maestroni, G. M. I. (1995). T-helper-2 lymphocytes as a peripheral target of melatonin. J Pineal Res, 18, 84-9.
28. Maestroni, G. J. M., Covacci, V. and Conti, A. (1994). Hematopoietic rescue via T-cell-dependent, endogenous GM-CSF by the pineal neurohormone melatonin in tumor bearing mice. Cancer Res, 54, 2429-32.
29. 125]Iodomelatonin by partially purified membranes of rat thymus. J Neuroimmunol, 45, 121-6.
30. Muzzioli, M., Pierpaoli, W. and Fabris, N. (1994). The immune-reconstituting effect of melatonin or pineal grafting and its relation to zinc pool in aging mice. J Neuroimmunol, 53, 189-201.
31. 125I]Iodomelatonin by rat splenocytes: Characterization and its role on regulation of cyclic AMP production. J Neuroimmunol, 57, 171-8.
32. Steinhhilber, D., Brungs, M., Werz, O., et al. (1995). The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem, 270. 7073-40.
33. Turnlund, J. R., Durvin, N., Costa, F., et al. (1986). Stable isotope studies of zinc absorption and retention in young and elderly men. J Nutr, 116, 1239-47.
34. Fabris, N., Mocchegiani, D., Muzzioli, M., et al. (1991). The role of zinc in neuroendocrine-immune inuteactions during aging. Ann N Y Aca Sci, 61, 314-26.
35. Morton, D. J. (1990). Alteration of plasma cation levels in rats kept in constant light. J Pineal Res. 9, 95-101.
36. Maestroni, G. M. I., Conti, A. and Lissoni, P. (1994). Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res, 54, 4740-3.
37. Kuby Janis (1994). Function of cytokines. In: Immunology. New York: W. H. Freeman and Company, 302-4.
38. Cristina, M. C., Daniela, F., Giuseppe, N., et al. (1992). Melatonin as immunomodulator in immunodeficient mice. Immunopharmacology, 23, 81-9.
39. Lucas, L. C., Guan-Jie, C., Maria, C. L., et al (1992). Melatonin induced increase in gamma-interferon production by murine splenocytes. Immunol Lett, 33, 123-6.
40. Lissoni, P., Barni, S., et al. (1989). Endocrine and immune effect of melatonin therapy in metastic cancer patients. Eur J Cancer Clin Oncol, 25, 789-95.
41. Kuribayashi, K., Gillis, S., Kern, D. E., et al. (1981). Murine NK cell culture: Effects of interleukin-2 and Interferon on cell growth and cytotoxic reactivity. J Immunol, 126, 2321-7.
42. Smith, K. A. (1988). Interleukin-2: inception, impact and implication. Science, 240, 1169-76.
43. Grabstein, K., Dower, S., Gillis, S., et al. (1986). Expression of interleukin 2, Interferon-γ, and the IL 2 receptor by human peripheral blood lymphocytes. J Immunol, 136, 4503-8.
44. Banchereau, J. (1991). Interleukin-4. In: Thomson A., editor. The cytokine handbook. London: Academic Press. 119-49.
45. Withyachumnarnkul, B., Nonaka, K. O., Santana, C., et al. (1990). Interferon-gamma modulates melatonin production in rat pineal gland in organ culture. J interferon Res, 10, 403-11.
46. Money, K. M., Mclachlan, L. A. and Bakouche, O. (1994). Activation of human monocytes by the pineal hormone melatonin. J Immunol, 152, 2671-80.
47. Georges, J. M., Maestroni, A. C. and Walter Pierpaoli (1986). Role of the pineal gland in immunity: Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol, 13, 19-30.
48. Holdaway, I. M., Mason, B. H., Gibbs, E. E., et al. (1991). Seasonal changes in serum melatonin in women with previous breast cancer. Br J Cancer, 64, 149-53.
49. Blask, D. E. and Hill, S. M. (1988). Melatonin and cancer: aspects in Miles A. In: Philbrick D. R. S., Thompson C., editors. Melatonin-Clinical Prospectives. Oxford: Oxford Medical Publications, 128-73.
50. Bartsch, C, Bartsch, H., Fuchs, U., et al. (1989). Stagedependent depression of melatonin in patients with primary breast cancer: correlation with prolactin, thyroid stimulating hormone and steroid receptors. Cancer, 64, 426-33.
51. Bartsch, C., Bartsch, H., Bellmann, O., et al. (1991). Depression of serum melatonin in patients with primary prostate cancer is not due to an increased peripheral metabolism. Cancer, 67, 1681-4.
52. Bartsch, C., Bartsch, H., Fluchter, S. H., et al. (1985). Evidence for modulation of melatonin secretion in men with benign or malignent tumors of the prostate: relationship with the pituitary hormones. J Pineal Res. 2, 121-32.
53. Bartsch, C., Bartsch, H., Fluchter, S. H., et al. (1994). Diminished pineal function coincides with disturbed circadian rhythmicity in untreated primary cancer patients: consequence of premature aging or of tumor growth? Ann NY Acad Sci, 719, 502-25.
54. Lapin, V. and Frowein, A. (1981). Effects of growing tumors on pineal melatonin levels in male rats. Journal of Neurotransmitters, 52, 123-36.
55. Bartsch, C., Bartsch, H. and Gupta, D. (1990). Pineal melatonin synthesis and secretion during induction and growth of mammary cancer in female rats. In: Gupta D., Wollman, Ranke M. B., editors. Neuroendocrinology: new frontiers. London, Tubingen: Brain Research Promotion, 326-32.
56. Bartsch, H., Bartsch, C., Simon, W. E., et al Antitumor activity of the pineal gland: Effect of unidentified substances versus the effect of melatonin. Oncology, 49, 27-30.
57. Bartsch, C., Bartsch, H., Buchberger, A., et al. (1995). Serial transplants of DMBA-induced mammary tumors in Fischer rats as model system for human breast cancer. Oncology, 52, 279-83.
58. Hill, S. M., Spriggs, L. L., Simon, M. A., et al (1992). The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett, 64, 249-56.
59. Blask, D. E. and Hill, S. M. (1986). Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. Journal of Neurotransmitters Suppl., 21, 433-49.
60. Wilson, S. T., Blask, D. E. and Lemus-Wilson, A. M. (1992). Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J Clin Endocrinol Metab, 75, 669-70.58.
61. Lissoni, P., Barni, S., Meregalli, S., et al (1995). Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer, 71, 854-6.
62. Barni, S., Lissoni, P., Cazzaniga, M., et al. (1995). A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology, 52, 243-5.
63. Cos, S. and Sanchez-Barcelo, E. J. (1994). Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation. Cancer Lett, 85, 105-9.
64. Tommasi, M. S., Brocchi, A., Fiorelli, C, et al.(1993). Effects of melatonin on cytokine production in patients with advanced solid tumors. Euro-Immunoanalyse, Lyon France, 4-5.
65. Bruno, N., Carlo, F., Fausto, M., et al (1994). Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. Cancer, 73, 3016-9.
66. Wanebo, H. J., Pace, R., Hargett, S., et al (1985). Production and blood lymphocytes of cancer patients. Cancer, 57, 656-62.
67. Lissoni, P., Barni, S., Ardizzoia, A., et al. (1992). Randomized study with the pineal hormone melatonin versus supportive care alone in advanced non-small cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology, 49, 336-9.
68. Lissoni, P., Tisi, E., Barni, S., et al (1992). Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer, 66, 155-8.
69. Maestroni, G. J., Covacci, V. and Conti, A. (1994). Hematopoietic rescue via T-cell dependent, endogenous granulocyte-macrophage colony stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. Cancer Res, 54, 2429-32.
70. Lissoni, P., Meregalli, S., Fossati, V., et al. (1994). A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori, 80, 464-7.
71. Aldeghi, R., Lissoni, P., Barni, S., et al. (1994). Low-dose Interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer, 30(A), 167-70.
72. Lissoni, P., Barni, S., Tancini, G., et al. (1993). Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. Br J Cancer, 67, 1404-7.
73. Lissoni, P., Barni, S., Cazzaniga, M., et al. (1994). Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose 1L-2 in patients with advanced solid tumors who had progressed on IL-2 alone. Oncology, 51, 344-7.
74. Lissoni, P., Barni, S., Tancini, G., et al. A randomized study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melatonin. Br J Cancer, 69, 196-9.
75. Lissoni, P., Barni, S., Brivia, F., et al. (1995). A biological study on the efficacy of low-dose subcutaneous interleukin2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology, 52, 360-2.
76. Reiter, R. J. (1991). Pineal gland: Interface between the photoperiodic environment and the endocrine system. Trends Endocrinol Metab, 2, 13-9.
77. Reiter, R. J. (1991). Pineal melatonin: Cell biology of its synthesis and of its physiologic interactions. Endocr Rev, 12, 151-80.
78. Ben-Nathan, D. and Feuerstein, G. (1990). The influence of cold or isolation stress on resistance of mice to West Nile virus encephalitis. Experientia, 46, 285-90.
79. Neri, B., Brocchi, A. and Cagnoni, M. (1995). Effects of melatonin administration on cytokine production in patients with advanced solid tumors. Oncology Reports, 2, 45-7.
80. Baiter, M. (1995). Cytokines move from the margins into the spotlight. Science, 268, 205-6.
81. Steinhilber, D. B., Brungs, M. and Carlberg, C. (1995). The nuclear recepter for melatonin represses 5-lipoxygenase gene expression in human B-lymphocytes. J bio chem, 270, 7037-40.
82. Russel, J. R. and Robinson, J. O. editors. (1995). Melatonin. New York: Bantam Books, 47-58.
83. Buttke, T. M. and Sandstrom, P. A. (1994). Oxidative stress as a mediator of apoptosis. Immunol Today, 15, 7-10.
84. Zeller, J. (1991). Immune mechanism in AIDS. In: Durham J. D., Cohen F. I., editors. The person with AIDS: Nursing perspective. New York: Springer Publishing Co, 60-71.
85. Yarchoan, R., Mitsuya, H. and Broder, S. (1993). Challenges in the therapy of HIV infection, Immunol Today, 361-84.
86. Tan, D. X., Chen, L. D. and Reiter, R. J. (1993). Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocri J, 1, 57-60.
87. Viswanathan, M., Laitinen, J. T. and Saavedra, J. M. (1990). Expression of melatonin receptors in arteries involved in thermoregulation. Proc Natl Acad Sci, 87, 1165-71.
88. Lopez-Gonzalez, M. A., Calvo, J. R., Rubio, A., et al. (1991). Characterization of melatonin binding sites in the rderian gland and median eminence of the rat. Life Sci. 48, 1165-71.
89. Morgan, P. J. (1991). Molecular signaling via the melatonin receptor. Adv Pineal Res. 5, 191-7.
90. Reiter, R. J. editor. (1984). The pineal gland: New York, 1-200.